Men and women may be affected differently by retinitis pigmentosa, a disease that causes blindness over time. That's ...

Aldeyra Therapeutics received FDA fast track designation for ADX-2191 for the treatment of retinitis pigmentosa, according to ...

ADX-2191 is a preservative-free intravitreal formulation of methotrexate designed to treat various rare retinal diseases such as retinitis pigmentosa.

Cyte initiates patient dosing in a new trial for famzeretcel, aiming to transform treatment options for retinitis pigmentosa.

NEWPORT BEACH, Calif., August 18, 2025--jCyte, Inc. is pleased to announce the first patients have been enrolled and treated ...

In this Healio Video Perspective from the Retina World Congress, Huma Qamar, MD, MPH, of Ocugen, overviews programs for ...

Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra) today announced that the U.S. Food and Drug Administration (FDA) has granted fast track designation for ADX-2191 (methotrexate intravitreal ...

Aldeyra (ALDX) announced that the FDA has granted fast track designation for ADX-2191 for the treatment of retinitis pigmentosa. There is ...

Other causes of retinitis pigmentosa Non-inherited or non-genetic causes of retinitis pigmentosa are rare. This means that it is rare to find a case where there is no family history of the condition.

With this milestone, VG801 now holds RMAT, Rare Pediatric Disease, and Orphan Drug designations. VeonGen has also been selected to collaborate with the FDA under the Rare Disease Endpoint Advancement ...